FORT WORTH, Texas, March 16 /PRNewswire/ -- Healthpoint today announced that it has initiated a Phase II clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The study is designed to determine the effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to placebo plus standard care, in healing venous leg ulcers over a 12-week treatment period.
“Commencement of enrollment for this trial represents an important milestone in the development program for this novel biologic therapy,” commented Bert Slade, MD, FAAAAI, Chief Medical Officer at Healthpoint. “This second Phase II study will extend our understanding of this agent, which we believe will add to the promising results obtained in previous European clinical trials.”
The study is a randomized, double blind, dose-finding study involving subjects 18 years of age and older with venous leg ulcers of at least 6 week’s, but not more than 24 months duration. The ulcers must be between 2 cm2 and 12 cm2 in area at presentation. Approximately 400 subjects will be recruited at 25 investigational centers in the United States. The study will assess both the time to complete wound closure and the proportion of complete wound closures in each cohort.
Venous leg ulcers are increasingly common and costly, and are often a cause of prolonged suffering for patients. These wounds can be characterized as difficult to heal and are typically caused by impaired microcirculation secondary to venous hypertension. Many venous ulcers fail to heal even after 3 months of standard treatment and develop into chronic, non-responsive wounds. Based on an estimated figure of 2.5 million venous leg ulcers in the United States alone and a study of actual direct treatment costs of $9,685 per person, the annual cost of treating these wounds is likely in the many billions of dollars. Accordingly, the availability of innovative and effective treatment strategies for such high-risk wounds could provide tremendous benefits to both patients and society.
“The novel format of this cell-based therapy shows great potential to deliver a compelling clinical and cost effectiveness profile,” said Travis E. Baugh, President and Chief Operating Officer of Healthpoint. “The current study is an important part of our ongoing development strategy for advancing wound care therapies and our intended evidence-based dossier for regulatory filings in both the United States and Europe.”
About HP802-247
HP802-247 consists of two components that are sprayed sequentially on the wound bed at the time of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts.
Based on in vitro studies, HP802-247 is expected to release various growth and angiogenic factors into the micro-environment of the wound through administration of these living, metabolically active, but non-proliferating cells that are trapped on the wound surface in a thin fibrin matrix. The secreted growth and angiogenic factors are anticipated to stimulate the patient’s own cells to heal the wound.
About HEALTHPOINT, Ltd.
Since 1992, HEALTHPOINT has been dedicated to innovative technologies for the prevention and treatment of acute, chronic and burn-related wounds. The company is presently focused on the research and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: Collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, HYDROFERA BLUE(R) Bacteriostatic Wound Dressings, and SURGICEPT(R) Waterless Surgical Hand Antiseptic. HEALTHPOINT is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE(R). To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com(R). HEALTHPOINT is a DFB Pharmaceuticals, Inc. affiliate company, and is based in Fort Worth, Texas. For more information, visit the HEALTHPOINT website at www.healthpoint.com.
OASIS is a registered trademark of Cook Biotech, Inc.; HYDROFERA BLUE is a registered trademark of Hydrofera, LLC.
SANTYL, SURGICEPT, THE WOUND INSTITUTE, and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.
CONTACT: Robert Bancroft, General Manager of Healthpoint, +1-800-441-8227,
or rob.bancroft@healthpoint.com
Web site: http://www.healthpoint.com/
http://www.TheWoundInstitute.com/
